[go: up one dir, main page]

EA199900345A1 - Фармацевтические композиции, содержащие ламивудин и зидовудин - Google Patents

Фармацевтические композиции, содержащие ламивудин и зидовудин

Info

Publication number
EA199900345A1
EA199900345A1 EA199900345A EA199900345A EA199900345A1 EA 199900345 A1 EA199900345 A1 EA 199900345A1 EA 199900345 A EA199900345 A EA 199900345A EA 199900345 A EA199900345 A EA 199900345A EA 199900345 A1 EA199900345 A1 EA 199900345A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lamivudin
zidovudin
pharmaceutical compositions
compositions containing
hiv
Prior art date
Application number
EA199900345A
Other languages
English (en)
Other versions
EA002437B1 (ru
Inventor
Гэри Уэйн Гудсон
Аллен Уэйн Вуд
Кэтрин Джиннетт Форд
Original Assignee
Глаксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксо Груп Лимитед filed Critical Глаксо Груп Лимитед
Publication of EA199900345A1 publication Critical patent/EA199900345A1/ru
Publication of EA002437B1 publication Critical patent/EA002437B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Описаны фармацевтическая композиция и способ ингибирования вируса иммунодефицита человека (ВИЧ), при котором пациенту, инфицированному ВИЧ, вводят однородную комбинацию ламивудина, зидовудина и фармацевтического глиданта в количестве, которое обеспечивает противовирусную эффективность.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199900345A 1996-10-31 1997-10-29 Фармацевтические композиции, содержащие ламивудин и зидовудин EA002437B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9622681.6A GB9622681D0 (en) 1996-10-31 1996-10-31 Pharmaceutical compositions
PCT/EP1997/005953 WO1998018477A2 (en) 1996-10-31 1997-10-29 Pharmaceutical compositions containing lamivudine and zidovudine

Publications (2)

Publication Number Publication Date
EA199900345A1 true EA199900345A1 (ru) 2000-02-28
EA002437B1 EA002437B1 (ru) 2002-04-25

Family

ID=10802224

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900345A EA002437B1 (ru) 1996-10-31 1997-10-29 Фармацевтические композиции, содержащие ламивудин и зидовудин

Country Status (43)

Country Link
EP (1) EP0941100B1 (ru)
JP (1) JP2001502718A (ru)
KR (1) KR100551652B1 (ru)
AP (1) AP1067A (ru)
AR (1) AR009135A1 (ru)
AT (1) ATE241364T1 (ru)
AU (1) AU736607B2 (ru)
BG (1) BG64541B1 (ru)
BR (1) BR9712614A (ru)
CA (1) CA2270174A1 (ru)
CO (1) CO4930269A1 (ru)
CY (1) CY2485B1 (ru)
CZ (1) CZ296080B6 (ru)
DE (1) DE69722433T2 (ru)
DK (1) DK0941100T3 (ru)
EA (1) EA002437B1 (ru)
EE (1) EE03806B1 (ru)
ES (1) ES2200204T3 (ru)
GB (1) GB9622681D0 (ru)
GE (1) GEP20022735B (ru)
GT (1) GT199700116A (ru)
HR (1) HRP970569B1 (ru)
HU (1) HU224969B1 (ru)
ID (1) ID18698A (ru)
IL (1) IL129422A0 (ru)
IS (1) IS5024A (ru)
MY (1) MY119513A (ru)
NO (1) NO317163B1 (ru)
NZ (1) NZ335153A (ru)
OA (1) OA11038A (ru)
PA (1) PA8441101A1 (ru)
PE (1) PE10099A1 (ru)
PL (1) PL190349B1 (ru)
PT (1) PT941100E (ru)
SI (1) SI0941100T1 (ru)
SK (1) SK284286B6 (ru)
SV (1) SV1997000090A (ru)
TR (1) TR199900950T2 (ru)
UA (1) UA64725C2 (ru)
UY (1) UY24766A1 (ru)
WO (1) WO1998018477A2 (ru)
YU (1) YU19999A (ru)
ZA (1) ZA979726B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
HUP0500217A2 (hu) * 2002-04-23 2005-06-28 Lupin Limited Tartós hatású, módosított hatóanyag-leadású mátrix készítmények
AU2003291457A1 (en) * 2002-11-08 2004-06-03 Glaxo Group Limited Pharmaceutical antiviral compositions
AU2004206821C1 (en) 2003-01-14 2009-10-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
AR045841A1 (es) * 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
CN114010776A (zh) 2010-06-09 2022-02-08 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
WO2013132208A1 (en) 2012-03-05 2013-09-12 Cipla Limited Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine
US20140234415A1 (en) * 2013-02-20 2014-08-21 Abbvie Inc. Tablet Dosage Forms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950652A (en) * 1987-03-23 1990-08-21 Hem Research, Inc. dsRNAs for combination therapy in the treatment of viral diseases
CZ285232B6 (cs) * 1991-05-16 1999-06-16 Glaxo Group Limited Protivirové směsi
GB9110624D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Combinations
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
HRP970569A2 (en) 1998-08-31
ID18698A (id) 1998-04-30
NO992091L (no) 1999-06-29
HUP0000344A3 (en) 2002-04-29
CA2270174A1 (en) 1998-05-07
EE9900175A (et) 1999-12-15
PE10099A1 (es) 1999-03-02
CO4930269A1 (es) 2000-06-27
PA8441101A1 (es) 2000-05-24
SV1997000090A (es) 1998-10-07
NZ335153A (en) 2001-04-27
KR20000052893A (ko) 2000-08-25
PL333143A1 (en) 1999-11-22
KR100551652B1 (ko) 2006-02-13
IS5024A (is) 1999-04-09
ZA979726B (en) 1999-04-29
ES2200204T3 (es) 2004-03-01
CY2485B1 (en) 2005-06-03
GB9622681D0 (en) 1997-01-08
HUP0000344A2 (hu) 2001-05-28
EE03806B1 (et) 2002-08-15
PT941100E (pt) 2003-10-31
EP0941100B1 (en) 2003-05-28
PL190349B1 (pl) 2005-11-30
ATE241364T1 (de) 2003-06-15
AP1067A (en) 2002-05-01
CZ296080B6 (cs) 2006-01-11
HK1020880A1 (en) 2000-05-26
GT199700116A (es) 1999-04-22
EA002437B1 (ru) 2002-04-25
WO1998018477A2 (en) 1998-05-07
JP2001502718A (ja) 2001-02-27
UA64725C2 (ru) 2004-03-15
GEP20022735B (en) 2002-07-25
AP9901519A0 (en) 1999-06-30
BG64541B1 (bg) 2005-07-29
UY24766A1 (es) 2000-12-29
DE69722433D1 (de) 2003-07-03
MY119513A (en) 2005-06-30
IL129422A0 (en) 2000-02-17
HU224969B1 (en) 2006-04-28
SI0941100T1 (en) 2003-12-31
DK0941100T3 (da) 2003-09-01
AU736607B2 (en) 2001-08-02
BR9712614A (pt) 1999-10-26
AR009135A1 (es) 2000-03-08
TR199900950T2 (xx) 1999-07-21
OA11038A (en) 2002-02-06
SK284286B6 (sk) 2005-01-03
SK57599A3 (en) 2000-06-12
YU19999A (sh) 2000-10-30
EP0941100A2 (en) 1999-09-15
WO1998018477A3 (en) 1998-06-18
BG103435A (en) 2000-04-28
NO317163B1 (no) 2004-08-30
NO992091D0 (no) 1999-04-29
DE69722433T2 (de) 2004-04-08
AU5314298A (en) 1998-05-22
CZ155799A3 (cs) 1999-10-13
HRP970569B1 (en) 2004-10-31

Similar Documents

Publication Publication Date Title
MXPA02006679A (es) Composicion farmaceutica.
EA200200812A1 (ru) Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение
DE60119968D1 (en) Hepatitis c tripeptid inhibitoren
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
BR9811121A (pt) Produto, composição farmacêutica, e uso de um produto
EA200000997A1 (ru) Гомогенные фармацевтические композиции, содержащие абакавир, ламивудин и зидовудин
GEP20002297B (en) Alpha-Substituted Pyrimidine-Thioalhyl and Alkyl-Ether Compounds, Method for Treatment of Individual Infected with the Immunodeficiency Virus
DE69521693D1 (de) Taxanderivate enthaltende arzneizubereitungen
EA199900345A1 (ru) Фармацевтические композиции, содержащие ламивудин и зидовудин
ATE310738T1 (de) Gesättigte 1,2-dithiaheterocyclische verbindungen enthaltende antivirale pharmazeutische zubereitungen
NO915116L (no) Ikke-glykosylerte human-interleukin-3-analogproteiner
DE69518840D1 (en) N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren
NO970847L (no) 2-£amino-6-(cyklopropylamino)-9H-purin-9-yl|-2-cyklopenten-1-metanol-succinat som anti-virusmiddel
EA199900843A1 (ru) Синтез 1,3-оксаселеноланнуклеозидов, их активность против вируса иммунодефицита человека и против вируса гепатита-b
MX9301922A (es) Composiciones para el tratamiento de infeccion y enfermedad ocasionadas por el virus de hepatitis b (hbv).
KR910018393A (ko) 항바이러스제로서의 비대칭 2-(포스포노메톡시)프로필 구아닌
KR960700741A (ko) 인터페론치료에 대한 무응답자의 c형 간염 치료방법(method of treating hepatitis c in non-pesponders to interferon treatment)
KR950702838A (ko) 인터루킨-4(IL-4)를 사용한 사람 면역결핍 바이러스(HIV) 복제의 억제방법(Method for inhibiting HIV replication using IL-4)
DE69706657D1 (de) Natürliches menschliches alpha interferon enthaltende pharmazeutische zusammensetzungen
HUP9903098A2 (hu) VX478, zidovudin és/vagy 1592U89 kombinációja és ezt tartalmazó gyógyszerkészítmény
DK1043974T3 (da) Liposomer indeholdende flergrenede peptidkonstruktioner til anvendelse mod human immundefektvirus
TW217986B (en) Compositions for the treatment of infection and disease caused by HBV
TW324663B (en) Interferon-ω(IFN-ω) as anti-HIV (human immune deficiency virus) agent
ATE350026T1 (de) Erhaltung von körpereigenen proteinen
ECSP972294A (es) Composiciones farmaceuticas

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU